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INTRODUCTION
Amyloidosis is a rare disorder that involves the deposition 
of misfolded protein in extracellular tissue.  Disease 
manifestations vary depending on the affected organs. 
Areas most often involved include the kidneys, gastroin-
testinal tract, heart, nervous system, and musculoskeletal 
system.  The most common type is AL amyloidosis, in 
which plasma cells produce an abundance of a 
monoclonal proteins that affect numerous organ systems. 
A second variety, AA amyloidosis, is associated with 
inflammatory diseases such as rheumatoid arthritis and 
inflammatory bowel disease. Finally, a heritable version of 
amyloidosis mediated by mutations in the transthyretin 
protein (TTR) has a predilection for deposition in peripheral 
nerves and cardiac tissue1. 
CASE PRESENTATION
A 72 year-old female with a history of non-ischemic 
cardiomyopathy (NICM) with an ejection fraction (EF) of 
30-35%, monoclonal gammopathy of undetermined 
significance (MGUS), and chronic kidney disease (CKD) 
Stage 4 presented to the ED with several weeks of 
intermittent dizziness, nausea with dry heaving, 
intermittent shortness of breath, and pleuritic chest pain. 
At the time of admission she denied exertional chest 
pain, lower extremity swelling, or recent weight gain. 
She endorsed stable four-pillow orthopnea, good urine 
output in response to her home dose of bumetanide, 
and adherence to all her medications as well as to a 
low salt diet.   
The patient was diagnosed with NICM in 2013 after 
presenting with rapidly progressive dyspnea on exertion, 
new lower extremity swelling, and five-pillow orthopnea. 
A CT of her thorax at that time showed hilar lymphade-
nopathy,  and t ransthorac ic  echocard iogram 
demonstrated an EF of 30%, decreased from 45% in 
2012. A cardiac catheterization in 2012 revealed no 
coronary artery disease, and, given her new hilar 
lymphadenopathy on imaging, an infiltrative process 
such as sarcoidosis or amyloidosis was suspected as a 
possible cause for her worsening heart failure. She 
underwent a fat pad biopsy at the time which was 
negative for amyloidosis.  To follow, a cardiac MRI 
revealed no definitive evidence of sarcoidosis or 
amyloidosis. Furthermore, the patchy, delayed 
mid-myocardial enhancement in the left ventricle was 
attributed to viral myocarditis and thus the likely cause 
for her new onset heart failure (Figure 1).  After diagnosis, 
the patient’s EF recovered to 65% with aggressive 
management, but declined again to 30-35% despite 
optimal therapy.  Transthoracic echocardiogram from 
this admission demonstrated an ejection fraction of 
35%, biventricular hypertrophy with a restrictive pattern, 
and biatrial enlargement (Figure 2).
Other relevant medical history includes an ablation for 
atrial tachycardia six months prior to this admission.  She 
also had a history of Protein S Deficiency complicated 
by pulmonary embolism requiring anticoagulation on 
warfarin.
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Figure 1. Cardiac MRI Figure 2. Four-chamber view of the patient’s echocardiogram, displaying ventricular 
wall thickening and granular appearing myocardium.
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Physical examination on admission revealed normal 
vital signs, lungs clear to auscultation with no crackles, 
cardiac exam with normal S1/S2 sounds, a tachycardic 
rate with regular rhythm and no murmurs, rubs, or 
gallops.  Pulses were normal and JVD was not present. 
Extremities were warm, well perfused and without any 
peripheral edema.  Labs were significant for a troponin 
elevation to 0.21 ng/mL (baseline 0.15 ng/mL) and 
pro-brain natriuretic peptide (pro-BNP) elevated to 
10,358 pg/mL compared to 4,700 pg/mL at her last 
admission 6 months earlier.  EKG showed normal sinus 
rhythm with first-degree AV block and low voltage 
(Figure 3), and chest x-ray showed no consolidations 
or pulmonary edema.
DIFFERENTIAL DIAGNOSIS
The patient’s presenting symptoms were attributed to 
an exacerbation of her chronic systolic heart failure, 
and she was admitted for diuresis and further 
management.  Despite this initial assessment and her 
elevated pro-BNP, she appeared euvolemic on 
subsequent examination with no elevation of jugular 
venous pressure, no peripheral edema, and clear lungs.
With this ambiguous clinical picture, a right heart 
catheterization was performed to assess her 
hemodynamics. The catheterization revealed a 
pulmonary capillary wedge pressure of 15 mm Hg, right 
atrial pressure of 18 mm Hg, and cardiac index of 1.6 L/
min/m2 consistent with low output heart failure. 
Despite her negative fat pad biopsy in the past, other 
clinical data (echocardiogram, EKG, past medical 
history, and physical examination) supported a diagnosis 
of amyloidosis.  Given the continued suspicion, an 
endomyocardial biopsy was performed at the time of 
her right heart catheterization and stained positive for 
Congo Red, consistent with a diagnosis of amyloidosis 
(Figure 4).  Further typing by mass spectrometry was 
performed at the Mayo Clinic Laboratory which showed 
hereditary ATTR amyloidosis with a Val122Ile mutation. 
OUTCOME AND FOLLOW-UP 
The patient continues to follow up with Cardiology, 
Nephrology and Hematology/Oncology for management 
of her cardiac amyloidosis.  She has remained stable on 
her medication regimen since discharge.  Further 
management decisions regarding her amyloidosis were 
deferred at time of discharge to await the results of mass 
spectrometry.  Unfortunately, ATTR amyloidosis does not 
respond to chemotherapy as AL amyloidosis may, and 
supportive care is the only management in cases 
ineligible for transplant2.  Typically, liver transplantation is 
used to remove the culprit organ for abnormal TTR 
synthesis, and heart transplant may be used in 
management of end stage heart failure secondary to 
Figure 3. Electrocardiogram findings from our patient demonstrating low voltage in 
the limb leads and 1st degree AV block
Figure 4. Endomyocardial biopsy slides from this case stained with Congo Red.  (A) 
In this figure the normal myocardium is off-white, and the areas of amyloid deposition 
are salmon-colored (Congo red stain; Bright field microscopy, 10X magnification). 
(B) Demonstrates Congo-red staining under a polarized filter.  In this figure, normal 
myocardium appears blue, collagen (fibrosis) is white, and amyloid deposits are 
yellow-green (Congo red stain; Polarized light microscopy, 10X magnification).
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cardiac amyloid2,3. Given her advanced age and need for 
combined liver-heart transplantation, she is not a 
candidate for these traditional therapies but may be 
eligible for clinical trials of small molecular inhibitors for 
ATTR amyloid4.
DISCUSSION
The diagnosis of cardiac amyloid is suggested by 
increased ventricular wall thickness and granular 
appearance of myocardium on echocardiogram 
(Figure 2) as well as low voltage on EKG (Figure 3). 
Tachyarrhythmias and prolonged PR and QT intervals 
are also often associated with cardiac amyloidosis, both 
of which were present in this patient.  As mentioned 
above, the patient had first-degree A/V block and a 
prolonged QT interval on admission (Figure 3), in 
addition to recent ablation for atrial tachycardia.
Cardiac MRI is helpful in identifying cardiac amyloidosis 
but is not very sensitive in the early stages of the disease2. 
This was likely the case in our patient, as the MRI was 
performed around the time of the patient’s initial 
presentation of heart failure.  The gold standard for 
diagnosis is endomyocardial biopsy (Figure 3), but this is 
not typically a first line diagnostic tool given the ease of 
obtaining biopsy samples from other sites, such as the 
abdominal fat pad or bone marrow.  Interestingly, 
abdominal fat pad and bone marrow biopsies will only 
verify the diagnosis of amyloidosis in 40-80% of cases5. 
This is particularly true in the Val122Ile mutation seen in 
our patient, where amyloid deposition is primarily 
confined to the heart2.  
Cardiac amyloidosis is among the most serious manifes-
tations of amyloidosis and is associated with poor 
prognosis and high mortality.  Median survival from 
diagnosis of this variant of ATTR amyloidosis is 
approximately 2-3 years1.  Once the diagnosis is made, 
management centers around supportive care and 
medical management of heart failure symptoms. 
Additionally, the underlying protein misfolding disorder 
should be treated, if possible, with chemotherapy in the 
case of AL amyloid and with liver transplant in the case 
of ATTR amyloid1.  As mentioned above, these patients 
are sometimes evaluated for dual liver-heart transplan-
tation depending on the severity of their disease3.
KEY POINTS
This case illustrates a presentation of cardiac amyloid 
with many classic diagnostic findings.  These include: 
EKG findings of first degree A/V block and low-voltage 
complexes, atrial tachyarrhythmia, and elevated pro-BNP 
without clear signs of overt volume overload. 
Unfortunately for this patient, her prognosis remains 
poor, but the case illustrates an important point - in cases 
of progressive non-ischemic heart failure with an unclear 
etiology, it is important to keep a broad differential and 
consider cardiac amyloid if clinical signs point toward the 
diagnosis.  Biopsies from non-cardiac tissue can provide 
important diagnostic information, possibly confirming 
the disease, but lack the sensitivity needed to completely 
rule out the disorder.  Endomyocardial biopsy remains 
the gold standard for diagnosis of cardiac amyloid and 
should be pursued if clinical suspicion for the disease 
remains high. 
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